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Abstract: Purpose: Corticosteroids remain the mainstay therapy for uveitis, a major 
cause of blindness in the working age population. However, a substantial number of 
patients cannot benefit from the therapy due to steroids resistance or intolerance. 
Tacrolimus has been used to treat refractory uveitis through systemic administration. The 
aim of this study was to evaluate the therapeutic potential of 0.03% tacrolimus eyedrop 
in mouse models of uveitis.  
Methods: 0.03% tacrolimus in perfluorobutylpentane (F4H5) (0.03% Tacrolimus/SFA) 
was formulated using a previously published protocol. Tacrolimus suspended in PBS 
(0.03% Tacrolimus/PBS) was used as a control. In addition, 0.1% dexamethasone (0.1% 
DXM) was used as a standard therapy control. Endotoxin-induced uveitis (EIU) and 
experimental autoimmune uveoretinitis (EAU) were induced in adult C57BL/6 mice using 
protocols described previously. Mice were treated with eyedrops three times/day 
immediately after EIU induction for 48 h or from day 14 to day 25 post-immunization (for 
EAU). Clinical and histological examinations were conducted at the end of the 
experiment. Pharmacokinetics study was conducted in mice with and without EIU. At 
different times after eyedrop treatment, ocular tissues were collected for tacrolimus 
measurement.  
Results: The 0.03% Tacrolimus/SFA eyedrop treatment reduced the clinical scores and 
histological scores of intraocular inflammation in both EIU and EAU to the levels similar 
to 0.1% DXM eyedrop treatment. The 0.03% Tacrolimus/PBS did not show any 
suppressive effect in EIU and EAU. Pharmacokinetic studies showed that 15 min after 
topical administration of 0.03% Tacrolimus/SFA, low levels of tacrolimus were detected 
in the retina (48 ng/g tissue) and vitreous (2.5 ng/ml) in normal mouse eyes, and the 
levels were significantly higher in EIU eyes (102 ng/g tissue in the retina and 24 ng/ml in 
the vitreous). Tacrolimus remained detectable in intraocular tissues of EIU eyes 6 h after 
topical administration (68 ng/g retinal tissue, 10 ng/ml vitreous). Only background levels 
of tacrolimus were detected in the retina (2-8 ng/g tissue) after 0.03% Tacrolimus/PBS 
eyedrop administration.  
Conclusion: 0.03% Tacrolimus/SFA eyedrop can penetrate ocular barrier and reach 
intraocular tissue at therapeutic levels in mouse eyes, particularly under inflammatory 
conditions. 0.03% Tacrolimus/SFA eyedrop may have therapeutic potentials for 
inflammatory eye diseases including uveitis. 
Keywords: Tacrolimus, semifluorinated alkane, uveitis, intraocular inflammation, eyedrop, pharmacolinetic. 
1. INTRODUCTION 
 Uveitis is an inflammatory condition of the uveal 
tract of the eye. Clinically, it can be classified into  
 
*Address correspondence to this author at The Wellcome-Wolfson 
Institute of Experimental Medicine, Queen’s University Belfast, 97 
Lisburn Road, BT9 7BL, Belfast, UK; Tel: +44 (0)289097 6463;  
E-mail: heping.xu@qub.ac.uk 
anterior, intermediate, posterior and pan uveitis based 
on the part of the uveal tract affected. Anterior uveitis 
accounts for 60-80% of all uveitis cases [1, 2]. Uveitis 
remains a significant cause of blindness in people of 
working age accounting for 10-15% of total blindness in 
the USA [3]. Uveitis can have infectious or non-
infectious (autoimmune) aetiologies. A recent study has 
shown that the prevalence of non-infections uveitis in 
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the USA is 121 people per 100,000 for adults and 29 
per 100,000 for children [4]. However, in Southern 
India, it has been reported that nearly one in 200 
persons may be affected by this condition [5].  
 Autoimmune uveitis is mediated by retinal antigen 
specific T lymphocytes, including Th1 and Th17 cells 
[6, 7], and corticosteroids remain the mainstay therapy 
for this condition. Anterior uveitis is treated with topical 
steroids, although systemic immune suppression may 
be required if patients also have other systemic 
autoimmune conditions. For posterior uveitis, apart 
from systemic immune suppression, intravitreal 
injection of steroids (e.g., dexamethasone, 
triamcinolone and fluocinolone) is now commonly used. 
Various intraocular implants have also been developed 
to improve intraocular drug delivery. Although 
intravitreal injection of steroids can better control 
inflammation [8] and cause limited systemic side-
effects, local adverse effects remain a major concern. 
For example, 30-50% of patients developed glaucoma 
following intravitreal injection of triamcinolone [9]; 
almost all patients received intravitreal injections of 
fluocinolone via the Retisert implant had glaucoma and 
40% of them required surgery to control the pressure 
[8]. Cataract is another common side-effect, particularly 
in patients receiving multiple intravitreal steroid 
injections [10]. Clearly, more effective and safer 
therapies are urgently needed for uveitis. 
 Tacrolimus (FK506), a macrolide lactone isolated 
from fungus, Streptomyces tsukubaensis is a potent 
immunosuppressive drug [11]. Tacrolimus has the 
same mechanical action of inhibiting T-lymphocyte 
signal transduction and cell proliferation as 
cyclosporine, but is 100 times more powerful [12-14]. 
Tacrolimus is used off label as a second line of therapy 
for uveitis through systemic administration and is 
proved to be effective, particularly in steroid-resistance 
or intolerance patients [15-17]. However, long-term 
usage can cause tacrolimus intolerance due to severe 
adverse effects (e.g., nephrotoxicity, hypertension, 
hyperesthesia, muscular weakness, insomnia, and 
central nervous system alterations, etc. [18]). Topical 
formulations of tacrolimus are not available due to the 
poor solubility and stability of the molecule in aqueous 
environments.  
 Semifluorinated alkanes (SFAs) are physically, 
chemically and physiologically inert, undergo neither 
catabolism nor metabolism in the human body and 
have favourable physical properties for use in the eye, 
including low surface and interface tension leading to 
excellent spreading properties [19]. Moreover, lipophilic 
drugs such as tacrolimus can be formulated without the 
use of surfactants and stabilizers. These properties 
make them ideal for ocular drug delivery [20]. Among 
the various SFAs, we explored perfluorobutylpentane 
(F4H5) for ophthalmic applications. Here we report the 
therapeutic potential of a novel formula of tacrolimus 
eyedrop i.e., 0.03% tacrolimus dissolved in F4H5, in 
mouse models of uveitis, including the endotoxin- 
 
 
induced uveitis (EIU), a model of human anterior 
uveitis, and retinal antigen peptide induced 
experimental autoimmune uveoretinitis (EAU), a model 
of human posterior uveitis.  
2. MATERIALS AND METHODS 
2.1. Animals  
 Ten- to 12-week-old C57BL/6J mice were supplied 
by the Biological Resource Unit at the Queen’s 
University Belfast. All procedures adopted conformed 
to the Home Office Regulations for Animal (Scientific 
Procedures) Act 1986 (UK) and to the Association for 
Research in Vision and Ophthalmology Statement for 
the use of Animals in Ophthalmic and Vision Research. 
All protocols were approved by the Ethics Committee of 
the Queen’s University Belfast.   
2.2. Induction of Experimental Autoimmune 
Uveoretinitis (EAU)  
 EAU was induced as previously described [21-23]. 
Briefly C57BL/6J mice were immunized 
subcutaneously with 500 µg of IRPB peptide 1–20 
(GPTHLFQPSLVLDMAKVLLD; GL Biochem, Shanghai 
Ltd., China) emulsified in complete Freund’s adjuvant 
(CFA, H37Ra, Difco Laboratories, Detroit, MI, USA). 
Mice were administered with an additional 
intraperitoneal injection of 100 µl (1.5 µg) of Bordetella 
pertussis toxin (Tocris Bioscience, UK). Retinal 
inflammation develops at day 12-14 post-immunisation 
(p.i.), and peaks at day 22-25 p.i. The severity of 
inflammation declines after the peak stage, however, 
retinal inflammation remains active for over 4 months 
[22].  
2.3. Induction of Endotoxin Induced Uveitis (EIU) 
 EIU was induced in C57BL/6J mice by intravitreal 
injection of lipopolysaccharide (LPS) using a previously 
described protocol [24, 25] with slight modification. In 
brief, Escherichia coli 055:B5 LPS (Sigma, UK) was 
dissolved in pyrogen-free phosphate buffered saline 
(PBS). Mice were injected intravitreally with 200 ng/eye 
LPS in 1 µL using a 30-gage needle and a 25 µL 
syringe in the Repeating Dispenser (PB600-1, 
Hamilton, Nevada, USA). Intraocular inflammation 
begins 4 to 6 hours after the LPS challenge, peaks at 
24-48 h, the inflammation then starts to resolve after 3 
days [25]. 
2.4. Formulations 
 A solution of 0.03% w/v of tacrolimus (Zhejiang 
Hisun Chemical Co., Ltd., China) in 1.4% w/w ethanol 
(Sigma-Aldrich, Germany) in perfluorobutylpentane 
(F4H5) (Novaliq GmbH) was formulated according to 
the procedure detailed in relevant Patents. Tacrolimus 
suspended in PBS (0.03%) was used as a control. In 
addition, 0.1% dexamethasone (DXM) (Sigma-Aldrich, 
UK) was used as a standard therapy control.  
 
A Low Concentration of Tacrolimus/Semifluorinated Alkane (SFA) Current Molecular Medicine, 2017, Vol. 17, No. 3    213 
2.5. Treatment  
2.5.1. Treatment of EAU  
 On day 14, EAU mice were divided into four groups 
based on the clinical score of inflammation and the 
score in each group was comparable. Group 1: Control 
(no treatment, n = 7 mice); Group 2: 0.1% 
Dexamethasone eyedrop (DXM, n = 7 mice); Group 3: 
0.03% Tacrolimus/PBS eyedrop (n = 7 mice); Group 4: 
0.03% Tacrolimus/SFA eyedrop (n = 7 mice). All mice 
in groups 2-4 received eyedrop treatment three times a 
day from day 14 p.i. - day 25 p.i.  
2.5.2. Treatment of EIU  
 Mice were randomized into four groups in the EIU 
study: Group 1: Control (no eyedrops, n = 6 mice); 
Group 2: 0.1% Dexamethasone treatment, N = 6 mice; 
Group 3: 0.03% Tacrolimus/PBS, n = 6 mice; Group 4: 
0.03% Tacrolimus/SFA, n = 8 mice. All mice were 
treated with eyedrops three times per day starting 
immediately after the intravitreal injection of LPS for 
two days. The study was repeated twice. 
2.6. Clinical Evaluation of Ocular Inflammation  
 Animals were anesthetized by isoflurane inhalation 
(Vet Tech Solutions Ltd., UK) and pupils dilated using 
1% atropine and 2.5% phenylephrine (Minims, Bausch 
and Lomb, UK). The severity of ocular inflammation 
was evaluated under the microscope taking into 
consideration of both anterior and posterior 
inflammation (by fundus examination using the fundus 
imaging system). The clinical score for anterior uveitis 
was graded according to a previously defined scoring 
system (grades 0-4) [26]: grade 0, no inflammatory 
reaction; grade 1, discrete inflammation of the iris and 
conjunctival vessels; grade 2, dilation of the iris and 
conjunctival vessels with moderate flare in the anterior 
chamber; grade 3, hyperemia in the iris associated 
with the Tyndall effect in the anterior chamber; and 
grade 4, same clinical signs as for 3 plus the presence 
of fibrin or synechiae. To evaluate retinal inflammation, 
fundus images were taken from each mouse using the 
Topical Endoscopic Fundus Imaging (TEFI) system as 
described previously [26]. Digital images from each eye 
were analysed and clinical score was assessed by two 
independent researchers using a standard grading 
system developed by us previously [26].  
2.7. Histology 
 Eyes were collected from day 25 p.i. EAU or day 2 
p.i. EIU mice for histological examination. All eyes were 
fixed in 2.5% (w/v) glutaraldehyde (Agar Scientific Ltd., 
Stansted, UK) for at least 24 h. Eyes were then 
embedded in paraffin and processed for haematoxylin 
and eosin (H&E) staining, and examined using a light 
microscope (Nikon Eclipse E400 light microscope; 
Nikon UK Ltd.) For each eye, four sections from four 
different layers 100 µm apart were graded according to 
the criteria described previously [27]. 
2.8. Pharmacokinetics Study of Tacrolimus/SFA 
Eyedrop 
2.8.1. Eyedrop Treatment and Groups  
 The pharmacokinetics of Tacrolimus/SFA eyedrop 
were conducted in both normal mice and EIU mice. 
Normal C57BL/6J mice or EIU mice (immediately after 
LPS injection) were treated with either 0.03% 
Tacrolimus/SFA or 0.03% Tacrolimus/PBS eyedrops 
(60 µL/drop) three times per day for three days. At 
different times (15 min, 30 min, 1 h, 2 h, 4 h and 6 h) 
after the last eyedrop treatment, animals were 
sacrificed and the following samples were collected for 
the measurement of tacrolimus (1) vitreous humour, (2) 
retina, (3) choroid/sclera, and (4) blood. Four mice 
were used in each group, and 20 normal mice and 8 
EIU mice that did not receive any eyedrop treatment 
were used as controls.  
2.8.2. Sample Collection and Processing  
 (1) Vitreous humour – 6 ~ 8 μL vitreous humour 
were collected from each mouse. (2) Retina – Retinal 
tissues were dissected and weighted immediately after 
sacrificing the animal and put into an Eppendorf tube. 
(3) Choroid/sclera – Chroroid/scleral tissues were 
dissected and weighted immediately after sacrificing 
the animal and put into an Eppendorf tube. (4) Blood – 
200 ~ 500 μL of whole blood were collected into EDTA-
coated tubes from each mouse.  
 All samples were stored at -20°C and then shipped 
to Nuvisan GmbH. Determination of tacrolimus was 
conducted at Nuvisan GmbH using an internally 
standardized liquid chromatography tandem mass 
spectrometry (LC-MS/MS) method, which was qualified 
for the respective matrices before sample analysis. The 
lower limit of quantification was 0.25 ng/mL for blood, 
0.05 ng/mL for retina and choroid/sclera homogenate, 
and 1.25 ng/ml for the vitreous.  
3. RESULTS 
3.1. The Effect of Tacrolimus/SFA Eyedrop in EIU 
 Clinical investigation revealed engorgement of 
conjunctival vessels, massive immune cell infiltration in 
the anterior chamber and the vitreous of untreated and 
tacrolimus-PBS treated EIU mice at 48 h (arrows, Fig. 
1A, B). Infiltrating cells were more frequently observed 
in the inferior part of the vitreous body (Fig. 1B). 
Retinal detachment and haemorrhage were observed 
in eyes with severe inflammation (arrow, Fig. 1C). The 
severity of intraocular inflammation was reduced 
following Dexamethasone (Fig. 1D) or Tacrolimus/SFA 
(Fig. 1E) treatment compared to control and 
Tacrolimus/PBS treated groups (Fig. 1F).  
 Consistent with the clinical signs, histological 
analysis revealed marked features of EIU characterized 
by accumulation of immune cells in the anterior 
chamber (AC), vitreous cavity (Vi), and ciliary body 
(CB) area in mice with no treatment (Fig. 2A) or  
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Tacrolimus/PBS eyedrop treatment (Fig. 2B). Severe 
retinal destruction (retinal detachment, disorganised 
retinal layers, haemorrhage) associated with massive 
retinal immune cell infiltration was also observed 
(arrows in Fig. 2A, B). Mild cell infiltration in the 
vitreous and retina was observed in eyes treated with 
DXM or Tacrolimus/SFA eyedrops, and the overall 
architecture of retinal layers remained intact (Fig. 2C, 
D). The histopathological scores in DXM and 
Tacrolimus/SFA treated eyes were significantly lower 
than that from untreated control EIU eyes (Fig. 2E). 
Repeated studies in additional two sets of mice 
revealed similar results. 
3.2. The Effect of Tacrolimus/SFA Eyedrop in EAU 
 Having shown that Tacrolimus/SFA eyedrop 
suppressed inflammation in EIU, we further tested its 
therapeutic effects in EAU, a mouse model of posterior 
uveitis. Topical administration of eyedrops was started 
after the onset of uveitis i.e., 14 days post-
immunisation (p.i.). Clinical scores of EAU were 
comparable between study groups prior to treatment 
(i.e., day 14). Severe retinal inflammation, 
characterised by extensive retinal infiltration (whitish 
lesions, Fig. 3A, B), vascular cuffing (arrows, Fig. 3A), 
and linear lesions (arrowhead, Fig. 3A) was observed 
in untreated and Tacrolimus/PBS treated EAU mice. 
Mild inflammation characterized by discrete small 
infiltrates, mild vascular cuffing and optic head swelling 
(Fig. 3C, D) was observed in dexamethasone and 
Tacrolimus/SFA treated eyes. The severity of retinal 
inflammation increased from day 14 to day 25 p.i. in all 
groups, although the increment was more significant in 
untreated and Tacrolimus/PBS treated groups 
compared to Tacrolimus/SFA and DXM treated groups 
(Fig. 3E). On day 25 p.i., the clinical scores of the DXM 
and Tacrolimus/SFA treated groups were significantly 
lower than those from untreated mice (Fig. 3F).  
 Histological examination revealed massive immune 
cell infiltration in the retina and vitreous in eyes from 
untreated (Fig. 4A) and Tacrolimus/PBS treated (Fig. 
4C) mice. Retinal layers were disorganised in these 
eyes. Small numbers of immune cell infiltration and 
granulomatous lesions (arrows, Fig. 4) were observed 
in DXM (Fig. 4B) and Tacrolimus/SFA (Fig. 4D) treated 
eyes, although the retinal structure was largely intact in 
these mice. The overall histopathological score of EAU 
was significantly lower in DXM treated and 
Tacrolimus/SFA treated mice compared to untreated 
controls (Fig. 4E). Our results suggest that DXM and 
Tacrolimus/SFA eyedrop is effective for the control of 
ongoing ocular inflammation in EAU. 
3.3. Pharmacokinetics and Absorption of 
Tacrolimus Eyedrop  
3.3.1. Pharmacokinetics and Absorption of 
Tacrolimus Eyedrop in Normal Non-Inflamed Mice 
 The levels of tacrolimus in the vitreous humour 
collected at 15 minutes to 2 h after Tacrolimus/SFA 
eyedrop treatment were between 2 ~ 6 ng/ml. By 4 h 
and 6 h, the level of tacrolimus was below detectable 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). The effects of Tacrolimus/SFA eyedrop on clinical presentations of EIU.  EIU was induced in mice by intravitreal 
injection of 200 ng/µl/eye LPS. Immediately after LPS injection, mice were treated with either 0.1% dexamethasone (DXM), or 
0.03% Tacrolimus/PBS, or 0.03% Tacrolimus/SFA eyedrop, 3 times/day. Clinical evaluation including fundus images were 
conducted after 48 h. (A-E) fundus images from untreated (A, C), Tacrolimus/PBS treated (C), DXM treated (D) and 
Tacrolimus/SFA treated (E) mice. Arrows in (A) and (B) indicating vitreous infiltrating cells; arrow in (C) indicating retinal 
haemorrhage. (F) Clinical score of retinal inflammation in different groups. Mann-Whitney test.   
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Fig. (2). Histopathology of EIU in different groups of mice. EIU mice were treated with 0.1% dexamethasone (DXM), or 
0.03% Tacrolimus/PBS, or 0.03% Tacrolimus/SFA eyedrops 3 times/day from day 0 to day 2. Eyes were collected on day 2 and 
processed for H-E staining. Light-microscopic images from (A) control untreated EIU mice, (B) Tacrolimus/PBS treated mice, (C) 
DXM treated mice, and (D) Tacrolimus/SFA treated mice. Arrows in (A) indicating retinal detachment; arrow in (B) indicating 
subretinal haemorrhage. (E) Histopathological score of retinal inflammation. One plot represents the score of one mouse (i.e., 
the average score of two eyes of a mouse). Mann-Whitney test. AC – anterior chamber; CB – ciliary body; Ir – iris; Vi – vitreous; 
Re – retina.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). The effects of Tacrolimus/SFA eyedrop on clinical presentation of EAU. EAU was induced in C57BL/6J mice using 
IRBP1-20 peptide immunisation. On day 14, mice were treated with different eyedrops 3 times/day. Fundus images were taken on 
day 25 post-immunisation from a control untreated EAU mouse (A), 0.03% Tacrolimus/PBS treated (B), 0.1% DXM treated (C), 
and 0.03% Tacrolimus/SFA treated (D) mice. Arrows in (A) and (D) indicating vascular cuffing; arrowhead in (A) indicating linear 
lesion. (E) Changes in clinical score of EAU from day 14 p.i. to 25 p.i. in different groups. Wilcoxon matched pairs test. (F) 
Comparing of clinical score of EAU on day 25 p.i. in different groups. Mann-Whitney test.    
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Fig. (4). Histopathology of EAU in different groups of mice. EAU mice were treated with 0.1% dexamethasone (DXM), or 
0.03% Tacrolimus/SFA eyedrops 3 times/day from day 14 to day 24. Eyes were collected on day 25 and processed for H-E 
staining. Light-microscopic images of (A) control untreated EAU mice, (B) DXM treated mice, (C) Tacrolimus/PBS treated mice, 
and (D) Tacrolimus/SFA treated mice. Arrows indicating granuloma lesions. (E) Histopathological score of retinal inflammation. 
One plot represents the score of one mouse (i.e., the average score of two eyes of a mouse). Mann-Whitney test. 
 
level in most of the samples in Tacrolimus/SFA treated 
mice. In Tacrolimus/PBS treated mice the Tacrolimus 
level was below the detectable level in all samples 
apart from those from 1 h. The level of Tacrolimus in 
the vitreous from Tacrolimus/SFA group was 
significantly higher than those from Tacrolimus/PBS 
group at 1 h after administration (Fig. 5A).  
 In the choroid/sclera, high levels of tacrolimus were 
detected at 15 minutes to 1 h after Tacrolimus/SFA 
eyedrop administration (276 ng/g tissue ~ 337 ng/g 
tissue, Fig. 5B). The levels then reduced to 150 ng/g 
tissue at 2 h and 70 ng/g tissue at 6 h (Fig. 5B). In eyes 
treated with Tacrolimus/PBS, 23 ng/g and 34 ng/g 
tissue of tacrolimus were detected between 15 min and 
1 h, and the levels reduced to 8 ng/g tissue by 6 h (Fig. 
5B). The levels of tacrolimus in the choroid/sclera in 
the Tacrolimus/SFA group at all time points were 
significantly higher than those in Tacrolimus/PBS group 
(Fig. 5B).  
 The levels of tacrolimus in the retina in the 
Tacrolimus/SFA were 48 ng/g tissue at 15 min after 
eyedrop administration, and increased to 90 ng/g tissue 
by 1 h (Fig. 5C). The levels of tacrolimus decreased 
slightly after 2 h, but remained at 53 ng/g tissue at 6 h 
after eyedrop treatment (Fig. 5C). In eyes treated with 
Tacrolimus/PBS, the levels of tacrolimus were between 
2-8 ng/g tissue at all time points and were significantly 
lower than those in eyes treated with Tacrolimus/SFA 
(Fig. 5C). 
 The level of Tacrolimus in the blood of normal mice 
treated with Tacrolimus/SFA increased from 35 ng/ml 
at 15 minutes to 118 ng/ml at 30 minutes and then 
reduced from 1 h but remained at 62 ng/ml at 2 h after 
treatment (Fig. 5D). Lower levels of tacrolimus (2-40 
ng/ml) were detected in the blood in mice treated with 
Tacrolimus/PBS eyedrop, although the levels were not 
statistically higher than those in untreated controls mice 
(Fig. 5D). The blood levels of tacrolimus in 
Tacrolimus/SFA group were significantly higher than 
those in Tacrolimus/PBS group at 30 min, 1 h, and 4 h 
time points (Fig. 5D).    
 Our results suggest that Tacrolimus/SFA has a 
greater permeability than Tacrolimus/PBS, and can 
rapidly penetrate ocular barriers in normal mouse eyes 
and distribute to all ocular tissues as well as the blood 
circulation rapidly (within 15 ~ 30 min) after eyedrop 
administration.   
3.3.2. Pharmacokinetics and Absorption of 
Tacrolimus Eyedrop in Uveitis Mice 
 Only Tacrolimus/SFA was tested in the uveitis eyes. 
Therefore, we compared the pharmacokinetics of 
Tacrolimus/SFA eyedrop between uveitis eyes and 
non-uveitis eyes. The levels of tacrolimus in the 
vitreous of uveitis mice were 24 ng/ml and 14 ng/ml at 
15 min and 30 min respectively, significantly higher 
than those in non-uveitis mice (2.5 ng/ml and 2.3 ng/ml 
respectively). Six hours after eyedrop administration 10 
ng/ml of Tacrolimus were detected in the vitreous of 
uveitis eyes compared to 1.1 ng/ml in non-uveitis eyes 
(Fig. 6A).  
 The level of Tacrolimus in the choroid/sclera was 
855.5 ng/g tissue at 15 min after eyedrop 
administration in uveitis mice compared to 276 ng/g 
tissue in normal mice (Fig. 6B). The concentrations of 
Tacrolimus decreased at 30 min and 1 h in uveitis eyes 
to the levels that were comparable to non-uveitis eye. 
At 2 h and 6 h, uveitis mice had significantly higher 
levels of Tacrolimus compared to normal non-inflamed 
mice (Fig. 6B).     
A Low Concentration of Tacrolimus/Semifluorinated Alkane (SFA) Current Molecular Medicine, 2017, Vol. 17, No. 3    217 
 Significantly higher levels of tacrolimus were 
detected in the retina of uveitis mice compared to that 
of non-uveitis mice after 15 min (102 vs. 48 ng/g tissue) 
and 2 h (115 ng/g vs. 61 ng/g tissue) (Fig. 6C) of 
administration. The level of retinal tacrolimus at 6 h 
was approximately 67% of that in 15 min in uveitis eyes 
(Fig. 6C).        
 The blood level of Tacrolimus was to 280 ng/ml in 
uveitis mice 15 min after administration, significantly 
Fig. (5). Tacrolimus levels in the vitreous, choroid/sclera, retina and blood of normal mouse eyes. Mice were given 
Tacrolimus/SFA or Tacrolimus/PBS eyedrop 3 times/day for 3 days. At different times after the last eyedrop treatment samples 
were collected and processed for measurement of Tacrolimus using the liquid chromatography tandem mass spectrometry (LC-
MS/MS) method. (A) Vitreous. (B) Choroid/sclera tissues. (C) Retinal tissues. The level of tacrolimus was normalized to tissue 
weight in retina and choroid/sclera. (D) Whole blood. Mean ± SD. N = 4, *P<0.05, **P<0.01, ***P<0.001 compared to 
Tacrolimus/PBS treated eyes at the same time point, 2-way ANOVA. +P<0.05, ++P<0.01 compared to Tacrolimus/PBS treated 
eyes at the same time point, unpaired t test. #, values below detectable in assay.  
Fig. (6). Tacrolimus levels in the vitreous of mouse eyes with and without uveitis. Control non-uveitis mice and uveitis 
mice were given Tacrolimus/SFA eyedrop 3 times/day for 3 days. At different times after the last eyedrop treatment samples 
were collected. (A) Vitreous. (B) Choroid/sclera tissues. (C) Retinal tissues. The level of tacrolimus was normalized to tissue 
weight in retina and choroid/sclera. (D) Whole blood. Mean ± SD. N = 4, *P<0.05, **P<0.01, ***P<0.001 compared to control 
non-uveitis eyes at the same time point. 2-way ANOVA. +P<0.05, ++P<0.01 compared to non-uveitis eyes at the same time 
point, unpaired t test. #, below detectable value in assay.  
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higher than that in non-uveitis mice (35 ng/ml) (Fig. 6D). 
The levels then decreased in uveitis mice to 143 ng/ml 
at 30 min and to 73 ng/ml at 6 h after eyedrop 
treatment. In non-inflamed mice, the blood levels of 
Tacrolimus increased at 30 min to the 118 ng/ml, and 
remained at the levels comparable to uveitis mice at 
other time points (Fig. 6D).  
4. DISCUSSION 
 Oral administration of tacrolimus is effective in 
uveitis refractory to corticosteroids and cyclosporine 
[15-17, 28]. Recent studies in non-infectious posterior 
uveitis patients have shown that tacrolimus 
monotherapy is as effective as the tacrolimus plus 
prednisone dual therapy in maintaining disease 
remission [29]. However, long-term systemic 
administration can cause tacrolimus intolerance [18]; 
therefore, local administration of tacrolimus would be 
an ideal option. Previous studies have demonstrated 
that intravitreal injection of tacrolimus is effective in 
controlling inflammation in experimental models of 
uveitis [30-32]. In this study, we show that 0.03% 
Tacrolimus/SFA eyedrop suppressed intraocular 
inflammation in both EIU and EAU models. Importantly, 
we show that Tacrolimus/SFA can rapidly penetrate 
ocular barrier at high levels, particularly in EIU eyes. 
Tacrolimus/PBS did not show any suppressive effect in 
EIU and EAU models, and it was unable to penetrate 
ocular barriers. Our results suggest that 0.03% 
Tacrolimus/SFA may be a novel therapy for intraocular 
inflammation.       
 Tacrolimus has a poor ability to penetrate tissue 
barrier upon topical administration due to its physico-
chemical properties [33]. Currently, a few tacrolimus 
formulations are being tested for ocular surface 
disorders such as allergic conjunctivitis [34-37], dry eye 
conditions [38], and high-risk corneal transplantation 
[39]. The formulas include 0.03% tacrolimus eye 
ointment (Protopic) and 0.03% tacrolimus eyedrop 
(Olive oil + 0.03% Tacrolimus, Ophthalmos Pharma, 
São Paulo, Brazil), 0.1% Tacrolimus ophthalmic 
suspension (Senju Pharmaceutical Co., Osaka, Japan), 
and 0.1% tacrolimus ophthalmic eye ointment 
(Tacimus-Ajanta Pharmaceuticals, India). The use of 
topical administration of tacrolimus to treat intraocular 
inflammation has not been reported, probably because 
none of the aforementioned products are capable of 
penetrating ocular barrier with therapeutic 
concentrations.    
 Recent studies have shown that semifluorinated 
alkanes act as an effective carrier for lipophilic drug 
cyclosporine for topical delivery [40]. In this study, we 
have used formulations of semifluorinated alkanes to 
dissolve tacrolimus. This formulation allows 0.03% 
tacrolimus to be dissolved completely to form a clear 
solution. The pharmacokinetic study suggests that 
Tacrolimus/SFA, but not Tacrolimus/PBS could rapidly 
(within 15 minutes) penetrate the tissue barriers (e.g., 
epithelial, membranes and endothelial barriers) after 
topical administration and reach choroid/sclera at 
significant levels in normal mouse.  At the same time a 
significant level of tacrolimus was observed in blood 
circulation. This is most likely due to direct absorption 
of tacrolimus from the ocular surface through the 
conjunctival vascular network. High blood levels of 
tacrolimus (along with local absorption) might 
contribute to high concentrations of tacrolimus in the 
choroid/sclera. 
 Absorption of tacrolimus is much increased when 
the eye is inflamed, and the levels of tacrolimus in the 
choroid/sclera and blood of uveitis mice were 3 and 8 
times higher than those in non-uveitis mice 15 min after 
administration.  
 Tacrolimus/SFA can penetrate not only general 
tissue barrier, but also the ocular barrier. Significant 
amounts of tacrolimus were detected in the vitreous 
and retina 15 min after topical administration and the 
drug remained in the retina for at least 6 h in normal 
mouse eyes. Further analysis is necessary to identify 
the source of intraocular tacrolimus, i.e., from the ciliary 
body and choroid or systemic blood circulation (via the 
inner BRB). 
 The levels of tacrolimus in the vitreous and retina 
were 2 and 10 times higher in uveitis eye than those in 
non-uveitis eyes at 15 min after administration. The 
pharmacokinetic data may explain the therapeutic 
effect of 0.03% Tacrolimus/SFA in the EIU and EAU 
models observed in this study.  
 A previous study in rabbit eyes using the 0.05% 
Tacrolimus suspension eyedrop has shown that the 
maximum concentrations of tacrolimus in the aqueous 
humour after a single dose and multiple doses of 
topical administrations were 31.4 ng/ml and 37 ng/ml 
respectively [41]. Another study showed that 1 h after 
1% Tacrolimus suspension eyedrop treatment, the drug 
concentrations in the conjunctiva, cornea, iris, and 
anterior sclera were 148, 900, 120, and 145 ng/g 
tissue, respectively, whereas the vitreous body 
concentration (Cmax) was only 1.4 ng/ml [42]. The 
present study in mice showed that 0.03% Tacrolimus 
eyedrop penetrates the ocular barrier (within 15 
minutes) and reach to intraocular tissues at high levels 
(2-6 ng/ml in the vitreous body and 48-116 ng/g tissue 
in the retina of normal mouse eyes).   
 The blood concentration of tacrolimus detected in 
this study after eyedrop administration in mice (34 ~ 
118 ng/ml in normal mice; 72 ~ 280 ng/ ml in uveitis 
mice) was significantly higher than that reported in the 
rabbit study (Cmax 2.7 ng/ml, after topical administration 
of 1% Tacrolimus suspension) [42]. It was also higher 
than that in human solid organ transplantation after 
systemic administration (trough blood concentration: 5 
~ 20 ng/ml) [43]. The discrepancies between our study 
and others may be due to the volume of eyedrop (e.g., 
standard drop size was used and not adjusted to the 
animal eye size), but more likely due to the higher 
penetration and large absorption area resulting from 
improved spreading of the Tacrolimus/SFA compared 
to 1% Tacrolimus suspension used in previous studies 
[42]. In our eyedrop formulation, tacrolimus is dissolved 
in SFA and therefore is available for absorption, 
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whereas the undissolved tacrolimus particles in the 1% 
suspension might be removed from, instead of 
absorbed by, the eye. Furthermore, difference in body 
size and in physiology and anatomy of the eyes 
between mouse, rabbit and man has to be considered 
when translating the results to humans [44, 45]. 
Therefore, further pharmacokinetics study in the rabbit 
or human eyes may help determine the clinical 
applications of 0.03% Tacrolimus/SFA in inflammatory 
ocular conditions.  
CONCLUSION 
 In conclusion, the data suggest that Tacrolimus/SFA 
is able to penetrate ocular barriers in mice, reach 
intraocular tissue at therapeutic levels and suppress 
retinal inflammation. Topical application of Tacrolimus/ 
SFA should have a potential in the management of 
inflammatory eye diseases such as uveitis although 
further studies are necessary to evaluate the long-term 
safety of this eyedrop and its therapeutic effects on 
recurrent or chronic uveitis.  
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